Vertex to stop developing new painkiller as solo treatment after mid-stage study setbackReuters • 08/04/25
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute PainBusiness Wire • 08/04/25
Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallBenzinga • 08/04/25
10 stocks favored to gain up to 30% in a sector that has missed this year's rallyMarket Watch • 07/31/25
Stay Ahead of the Game With Vertex (VRTX) Q2 Earnings: Wall Street's Insights on Key MetricsZacks Investment Research • 07/30/25
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 07/28/25
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial ResultsThe Motley Fool • 07/22/25
Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic FibrosisBusiness Wire • 07/14/25
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute PainBusiness Wire • 07/14/25
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than othersCNBC • 07/08/25
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key FactsZacks Investment Research • 07/01/25